May Become the World’s First Proven Cancer Preventive (and Something
Bigger) Ignored by Big Pharma
by Bill Sardi: Your
Money: Slip Sliding Away
It is not surprising
to learn that Big Pharma has shown no interest in what may become
the world’s first proven cancer prevention pill. If big profits
aren’t promised, pharmaceutical companies predictably pass on such
The pill is
a relatively safe FDA-approved generic drug, prescribed millions
of times to help control diabetes, and it costs maybe 10-cents a
day. But what is surprising is that public health authorities appear
to be remiss in announcing this breakthrough. They are the agency
in society commissioned to address important public health issues
such as this.
has been accumulating for 5 years now showing metformin (Glucophage),
an anti-diabetic drug, dramatically reduces the risk for cancer
and prolongs life among patients who are battling cancer.
The data does
not solely involve experiments with laboratory mice that often don’t
translate to humans. The data involves human studies.
big to-do that the New
York Times created in 1998 over a cancer drug that a Nobel
Prize winner said would "cure cancer in two years?" (That
quotation was later denied.) On the day that news story was released
the stock price soared for the company making the developmental
drug then said to cure cancer. But for metformin, a drug first approved
by the FDA in 1958, there is little fanfare. Its patent expired
years ago and it is a generic drug with low profitability. A quick
check on Google shows just six news outlets online are distributing
the story. Of the 7 billion people on the planet, how many will
learn of this?
If this were
some potential new blockbuster drug, the National Institutes of
Health would be grandstanding it in a press release and even a press
conference. Instead it is a news agency in this instance
News who is independently breaking the story (let’s hear
it for a free press). Bloomberg reporters quote a researcher who
says drug companies passed up sponsorship of studies involving metformin
and cancer when they realized their patents would expire before
the research study was completed.
science is moving too slowly towards adoption of such a pill. It
wants to conduct another decade of research before drawing any conclusions.
A number of large long-term
studies are underway but not scheduled to report any data till
haven’t ten years to wait. Whether oncologists begin to prescribe
it is another question. It isn’t being heralded in oncology journals.
The American Cancer Society website is ignoring this breakthrough
is the evidence? Very.
Just how convincing
is the currently available evidence? First, diabetics
have a much higher incidence of cancer. So it should not be
surprising that an anti-diabetic drug quells cancer.
risk of subsequent cancer diagnosis was significantly reduced among
patients with adult-onset diabetes who took metformin. The most
compliant patients were more protected against cancer than those
who failed to follow their pill regimen. Another study shows an
relative reduction in the risk for breast cancer among diabetics
taking metformin compared to other anti-diabetic drugs.
recently explored a database of thousands of diabetic subjects in
Tayside, Scotland. Cancer
was diagnosed among 7.3% of 4.085 metformin users and 11.6% of 4,085
non-metformin users. Metformin users tended to develop cancer
almost a year later than non-users.
that has gained much attention involves metformin among patients
with pancreatic cancer, a dire form of cancer where survival following
diagnosis is usually no greater than 1-2 years. Metformin produced
a significant 60%
relative reduction in ongoing risk for pancreatic cancer among
patients already diagnosed with the disease.
in 2009 showed that among 2,529 patients who underwent chemotherapy
for early-stage breast cancer, 24% of the patients who were taking
metformin experienced a "complete response" (cure) compared
to just 8% in the non-metformin group.
as these studies are, not
all show metformin is beneficial in preventing cancer.
a molecule found in the French lilac (botanical name: Galega officinalis),
and is now synthetically produced. Metformin is in a class by itself
when it comes to anti-diabetic drugs. It is the only anti-diabetic
medication that does not induce weight gain.
opportunity: more than a cancer pill
While it is
clear that a renaissance is underway in the use of metformin, this
time for cancer, it is sad to realize modern medicine could have
leaped at a decades- earlier opportunity to discover metformin’s
In the early
1970s Professor Vladimir Dilman pioneered the idea of molecules
called "biguanides’ as an anti-cancer drug as well as anti-aging
pill. Using phenformin, a close cousin to metformin, Dilman achieved
positive results, halting
a metabolic decline in immunity among post-operative (mastectomy)
breast cancer patients.
Professor Dilman was able to extend
the lifespan of mice by 23% and reduced tumor incidence by 80%
employing a relatively low dose of phenformin. This is better than
current life extension studies achieved with laboratory mice using
a widely heralded anti-aging molecule. It is clear what Dilman was
discovering was greater than a cancer cure it was a true anti-aging
was called a "geroprotector" just over a decade ago.
At about the
same time these studies by Vladimir Dilman and colleagues were being
conducted at the N.N. Petrov Research Institute of Oncology, St.
Petersburg, Russia, The
Society of Actuaries (insurance underwriters) was being privately
briefed on the development of an anti-aging pill. A report of
this meeting shows the topic of discussion was the scientific possibility
of extending life up to 250 years.
went on to proclaim that that such a discovery was "not ready
for widespread application in the field of medicine." It is
clear that the insurance industry squelched the idea of an anti-aging
pill because it would put them out of business. How do you sell
life insurance to a guy at age 30 when he’s going to live 250 years?
Professor Vladimir Dilman (1925-1994)
Did This Researcher Cure Cancer and Develop The First True Anti-Aging
Pill in the 1970s?
at the Petrov Research Institute would go ignored, not to be implemented.
Even now, while the promise of a true cancer cure is tantalizing,
the prospect of an even greater discovery is not being mentioned
– that of man’s impossible dream anti-aging pill.
cancer preventing molecules
metformin may not be the only molecule that can perform like this.
is often mentioned along with two other molecules, rapamycin,
a soil organism used as an immunosuppressive drug to treat rejection
of transplanted organs, and resveratrol, a red wine molecule, as
the most promising anti-aging agents. These three molecules are
known to mimic some of the biological effects of a calorie-restricted
uncover the key biological mechanisms that produce the anti-cancer
effects of metformin, they fail to recognize that even these mechanisms
are a result of something that goes unrecognized. These biological
mechanisms are not the driver behind the drug, they are the way
the effectiveness of the drug is measured. What IS the biological
driver is the ability of metformin
to chelate (key-late) or bind to unbound iron. It is accumulated
iron that drives up blood sugar levels. Blood letting, which
removes excess iron from the blood circulation, unequivocally resolves
insulin resistance among diabetics and is even used
in the treatment of cancer.
The very wide
array of side effects produced by metformin and rapamycin may be
due to their iron
has actually been used experimentally to counter the harsh effects
of a toxic cancer drug (doxorubicin) that releases iron and can
be damaging to the heart during treatment. In the animal lab, metformin
prevents damage to the heart during chemotherapy due to iron-induced
senescence, block cancer
have said that metformin’s primary action against cancer is its
ability to halt
the immortalization of cancer cells. Cancer cells don’t replicate
and then die off, they resist all efforts to kill them, what is
called treatment resistance.
One of the
recognized mechanisms of metformin is its ability to induce cellular
senescence. Cellular senescence is the phenomenon by which normal
cells lose their ability to divide, normally after about 50 cell
divisions in a lab dish. Therefore, senescent cells cannot replicate
and produce tumors. Like metformin, resveratrol
also induces cellular senescence.
gene target for both metformin and resveratrol is known as Target
of Rapamycin or mTOR. High
concentrations of resveratrol are required to significantly inhibit
mTOR at doses that approach toxic levels. Rapamycin, the other
oft-mentioned anti-aging molecule, actually
suppresses cell senescence. Though this should not be considered
a negative property as rapamycin is attempting to return the cell
to a youthful state.
A chart has
been created at the end of this report to help compare these three
molecules, metformin, rapamycin and resveratrol. The main point
here is that there may be more available alternatives to metformin,
which requires a doctor’s prescription. Doctors are not likely to
begin prescribing metformin to prevent cancer, let alone slow aging.
Meanwhile, resveratrol is widely available as a dietary supplement.
The medical profession will be quick to label resveratrol as an
unproven remedy, but actually all existing cancer treatments have
already been disproven, leaving cancer patients to search for available
metformin from resveratrol
It is well
established that blood serum and tissue concentrations of copper
are greatly increased in various malignancies. Resveratrol works
by selectively cleaving to or releasing copper based upon dose.
as a fat-soluble molecule is able to be transported across cell
membranes and enter the internal workings of cells. In high dose
will cleave to DNA in the cell nucleus and induce DNA breakage,
killing the cancer cell.
as a copper chelator appears to be superior to zinc or iron chelators
in regard to their cancer cell-killing properties. Because cancer
cells rely upon copper for growth and resveratrol targets copper,
this explains why
resveratrol destroys cancer cells but not healthy cells.
with resveratrol’s pro-oxidant cancer-killing action, even though
resveratrol targets cancer cells and not healthy cells, is that
given in high doses this molecule is concentrated in the kidneys
where it is excreted and becomes so toxic it can induce kidney failure.
This was shown in a controlled study conducted among terminal multiple
myeloma (bone-marrow) cancer patients who were given 5000
mg of resveratrol and rapidly experienced kidney failure. Modest
doses may be the best approach for cancer patients who are self-treating
to inducement of cellular senescence and inhibition of the mTOR
gene, resveratrol does this, but
at dose concentrations that are toxic. At low-dose concentration,
is an antioxidant and at high-dose concentration it promotes oxidation
proprietary resveratrol-based formula (Longevinex®) has been
shown to totally abolish
any toxicity at even the highest dose tested (2800 mg human
equivalent). While this would negate any direct cancer-killing effect,
this resveratrol-based formula exhibits strong ability to inhibit
new blood vessel formation required for tumors to receive nutrients
and grow (a
six-times greater effect than plain resveratrol). It has undergone
toxicity testing and exhibits no kidney toxicity in humans or animals
(unpublished). It also inhibits cancer via its ability to thin the
blood (clots promote the spread of cancer), inhibit inflammation,
and favorably control the immune response. This resveratrol formula
was also found to be the closest thing to a calorie restricted diet
as evidenced by its ability
to alter 677 of 831 known genes that are altered by a long-term
calorie-restricted diet in laboratory mice.
rapamycin and resveratrol incur the same fate as phenformin? Will
the public wait for their doctors to give them the go-ahead signal,
or bolt for these remarkable molecules on their own? It would not
be surprising to see cancer patients buy metformin online from offshore
sources that ship without a prescription. Any natural medicine that
even poses a threat to the $75
billion cancer drug market will likely be ignored. It is the
best way scuttle any threat to the $124
billion cancer industry. If the major TV news networks, Harvard
Medical School and your doctor say a promising anti-cancer agent
is unproven, that is the final word on that matter. Pity the unsuspecting
As for an
anti-aging pill, the overpopulation alarmists continue to beat their
drum despite the fact the count
of humans in Western Europe, Russia, Japan and North America, Brazil,
China and Australia is in decline. The problem is not over-population,
it is the cost of caring for a growing elderly population. In developed
countries, the size
of the elderly population has already surpassed that of the 12-24
age group. By dismissal of natural medicines, over-availability
of cheap nutrient-poor foods, and control of health choices via
insurance plans and medical school curriculums, modern medicine
has protected its market and ensured there is enough disease to
Of Three Cancer Preventive Medicines
Requires doctor’s Rx
(inhibits organ transplant rejection)
Island soil organism
(no longer capable of growing and dividing)
cancer in humans by
to 1.0 mg
than 350 mg
nausea, vomiting, flatulence, asthenia, indigestion, headache,
(6 in 100 patients)
(low dose safer)
edema, elevated blood pressure, diarrhea, abdominal pain,
headache, fever, anemia, nausea, elevated cholesterol/triglycerides
Achilles heel soreness
<! [if !supportLineBreakNewLine] >
<! [endif] >
(3 in 100,00)
infections, elevated cholesterol/triglycerides, thrombocytopenia
juice, many other drugs, herbs
!supportLists] >· <! [endif] >AMPK (AMP activated
protein kinase), which induces muscles to take up glucose
from the blood.
target of rapamycin
him mail] is a frequent writer on health and political
topics. His health writings can be found at www.naturalhealthlibrarian.com.
latest book is Downsizing
© 2012 Bill Sardi Word of Knowledge Agency, San Dimas, California.
This article has been written exclusively for www.LewRockwell.com
and other parties who wish to refer to it should link rather than
post at other URLs.
Best of Bill Sardi